GlycoMimetics makes good with $340m sickle cell drug deal with Pfizer
This article was originally published in Scrip
For a 22-employee biotech that just snagged a major deal with the world's largest drug maker, Gaithersburg, Maryland-based GlycoMimetics has much to be confident about, CEO Rachel King said, beaming about the new $340 million agreement her firm signed with Pfizer.
You may also be interested in...
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.